Connect with us

Technology

Kalderos Attracts Two Recognized Industry Leaders to Board of Directors

Published

on

New board members bring broad legal, regulatory, and corporate leadership experience across healthcare, biopharmaceutical, and pharmacy industries.

CHICAGO, Feb. 27, 2024 /PRNewswire/ — Data infrastructure and analytics company Kalderos, creator of the world’s first Drug Discount Management platform, today announced the addition of two experienced and highly respected industry veterans to its board of directors.

Joining the board are:

Robyn L. Peters, CEO and partner of consulting firm Sapere Health Solutions, with more than 30 years’ experience leading successful large-scale commercialization teams and critical turnarounds across biotech, biopharmaceuticals, and retail and specialty pharmacy providers.Bill Sarraille, a retired senior member of the Healthcare Practice group at Sidley Austin and nationally ranked lawyer in healthcare and administrative law widely known for his expertise in a broad array of healthcare matters, including Medicare and Medicaid reimbursement, coverage and coding, pharmaceutical price reporting, and 340B and other federal program compliance issues.

[To download a headshot of Peters, click here.]
[To download a headshot of Sarraille, click here.]

Peters and Sarraille will offer their respective expertise in helping guide Kalderos’ strategic direction and growth trajectory while ensuring its Drug Discount Management platform anticipates and exceeds the needs of stakeholders in compliance with laws, regulations, and industry standards.

“We are at an inflection point in this industry, where the systems and processes which have evolved over decades no longer enable the transparency nor build the trust necessary to ensure these programs empower better access to life-impacting medications and improve value-based patient care,” said Kalderos CEO Angie Franks. “We are so fortunate to have attracted two industry veterans whose diverse backgrounds will not only help Kalderos reach our milestones, but also offer privileged insight into the goals, needs, and challenges of our customer base.”

Scrutiny of government drug rebate and 340B purchasing programs continues to increase. In addition to the Inflation Reduction Act, 340B reform, the recent Genesis decision, and contract pharmacy litigation, Congress in February circulated draft legislation that would impose additional regulations on drug manufacturers, covered entities and state Medicaid agencies. Provisions in the early bill, called the SUSTAIN Act, would prohibit manufacturers from requiring the contract pharmacies of covered entities to collect data; define the term “patient”; establish new reporting requirements for 340B covered entities; and create a third-party entity to serve as a national clearinghouse to prevent duplicate discounts. 

The establishment of a national clearinghouse aligns closely with Kalderos’ goal to bring a claims-based 340B price effectuation model to market. Since its founding, Kalderos has established itself in the market as a convener, bringing more transparency and collaboration to ensure that access to these programs endures. The addition of the new board members adds experience and technical acumen to addressing these industry issues. 

Robyn Peters is an enormously accomplished global life sciences and healthcare executive leader and growth expert, while Bill Sarraille’s decades of legal experience have involved pharmaceutical manufacturers, Medicare, Medicaid, and the 340B program,” Franks said. “Their insights and guidance will be invaluable during this transitional time for the Medicaid Drug Rebate Program and the 340B Drug Pricing Program.”

About the Directors
Peters has led successful large-scale commercialization teams and critical turnarounds across biotech, biopharmaceuticals, and providers, including Pfizer, Inc., Walgreens Co., and Biogen. Recognized for her strategic leadership, Peters has driven innovation, pivoted growth strategies, and built high-performance teams that increased revenue growth and market capitalization in the billions of dollars. Peters’ commercial expertise spans biotech, retail and specialty pharmacy, payer, hospitals and health systems, and healthcare services with revenues ranging from $3 billion to $50 billion a year.

Before retiring as a senior partner in 2023, Sarraille was the regulatory lead and sought-after counsel in the biopharma / life sciences practice at Sidley Austin. Now serving as a regulatory consultant at his own advisory firm, Sarraille concentrates on a variety of healthcare regulatory, compliance, pricing, coverage, and patient access matters, including Medicare and Medicaid reimbursement, pharmaceutical price reporting, compliance program issues, 340B program issues, and managed care matters. He is the co-author of several healthcare books and served on the Regulatory Relief Committee for the American Hospital Association and on the Compliance Advisory Committee for the Healthcare Financial Management Association as its chairman.

About Kalderos
Kalderos is a data infrastructure and analytics company that created the world’s first Drug Discount Management platform, simplifying drug discount program compliance for all stakeholders. The platform applies sophisticated data models and machine learning to identify and resolve noncompliance, with collaboration-oriented solutions built for both drug manufacturers and covered entities. Based in Chicago, Kalderos was founded in 2016 by a team dedicated to reducing inefficiencies in the U.S. healthcare system, empowering everyone to focus on the health of people. More information can be found at www.kalderos.com

Media contact:
Philip Anast 
Amendola (for Kalderos) 
panast@acmarketingpr.com 
312-576-6990 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kalderos-attracts-two-recognized-industry-leaders-to-board-of-directors-302071793.html

SOURCE Kalderos

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

In Turfan, Xinjiang, China’s first commercially operated microgrid has generated nearly 100 million kWh of electricity

Published

on

By

TURFAN, China, Nov. 15, 2024 /PRNewswire/ — On November 13, the Turfan New Energy City Microgrid Demonstration Project, China’s first commercially operated microgrid demonstration project, generated nearly 100 million kWh of electricity, equivalent to saving 29,000 tons of standard coal and reducing carbon dioxide emissions by 77,600 tons.

A microgrid refers to a small-scale power generation and distribution system organized by distributed power sources, power loads, distribution facilities, monitoring and protection devices, etc., which can realize flexible control and autonomous management. Since the end of 2013, the project had been the largest and most comprehensive solar energy utilization and building integration project in China up to that time, with 8.7 MW of photovoltaic power installed on the roofs of 223 residential buildings, generating an annual power capacity of about 10 million kWh.

To promote the physical operation of the project, the State Grid Turfan Power Supply Company invested more than 2 million yuan to cooperate in the construction of microgrid infrastructure, fully supporting the online operation of surplus new energy power generation, promoting the comprehensive utilization of renewable resources in urban buildings, and helping Turfan build a high-quality development demonstration area and a green and low-carbon pilot area.

View original content:https://www.prnewswire.com/apac/news-releases/in-turfan-xinjiang-chinas-first-commercially-operated-microgrid-has-generated-nearly-100-million-kwh-of-electricity-302306810.html

SOURCE State Grid Turfan Power Supply Company

Continue Reading

Technology

Innovations in Guiyang: Adhering to New Industrialization and Promoting High-End, Intelligent and Green Manufacturing

Published

on

By

GUIYANG, China, Nov. 15, 2024 /PRNewswire/ — A report by Huanqiu.com

The wave of new industrialization in Guiyang is driving the transformation and upgrading of the manufacturing industry in ways like never before. Guiyang is always strategically oriented toward “industrial structure optimization with a focus on industries”, and has made all efforts to develop “four major industrial bases”, highlighting its industrial economy as the “primary driving force” behind development. Especially relying on its policy edge in renewable energy, Guiyang has rapidly emerged as a national new-energy power battery and materials research, development and production center, injecting strong momentum into the city’s economy.

In October 2023, the CATL (Guizhou) New Energy Power and Energy Storage Battery Production Base, located in Gui’an New Area, Guizhou Province, was put into production. The first phase of the base boasts cutting-edge design standards, characterized by “lighthouse + zero carbon factory”. The high-standard facility employs advanced, high-speed, highly automated, and flexible production lines. It is designed to have an annual production capacity of 30 GWh. After the base achieves the designed production capacity, its annual output value is expected to reach 15 billion yuan. According to statistics, the base realized an industrial output value of 618 million yuan in the first half of 2024, and the year’s industrial output value is expected at about 2 billion yuan.

The Chery (Guizhou) industrial base has also yielded unusually brilliant results in the field of new energy vehicles (NEVs), where Chery Automobile’s self-developed “CHEVOO” new-generation light truck KL71 project is undergoing four-pillar car road tests. The advanced pressing, welding, painting and assembly lines, as well as the R&D lab and the all-electric truck production line, together constitute this “digital intelligent” NEV factory. Moreover, the Chery (Guizhou) industrial base has built, extended and strengthened its vehicle manufacturing industry chain so as to master key parts supply chains and reduce development costs.

The Gui’an FinDreams battery project, as an important move of BYD in Guiyang, is also showing its strength in power batteries for NEVs. FinDreams Battery Co., Ltd. at Longshan Industrial Park in Gui’an New Area has four automatic production lines that are operating at high speeds in the workshop, which produce “blade batteries” which are well-known both in and out of the industry. According to reports, 300 battery packs and 40,000 cells can be produced per day.

Guiyang’s “four bases” – a new energy vehicles and battery materials production base, a resource deep-processing base, a computing power assurance base, and an industrial backup base, contribute greatly to the development of NEV and battery materials industry, electronic information manufacturing industry, and advanced equipment manufacturing industry, etc. Data show that in the first three quarters, the added value of Guiyang’s industrial enterprises above designated size grew by 11%, and the contribution of industrial economy to economic growth reached 39.4%.

Photo – https://mma.prnewswire.com/media/2558773/image.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/innovations-in-guiyang-adhering-to-new-industrialization-and-promoting-high-end-intelligent-and-green-manufacturing-302306825.html

Continue Reading

Technology

Premialab appointed by Lombard Odier Investment Managers to scale Quantitative Investment Strategies

Published

on

By

Premialab’s technology chosen to enhance QIS scaling, operational efficiency, and risk management.

PARIS, Nov. 15, 2024 /PRNewswire/ — Lombard Odier Investment Managers (LOIM), the institutional asset management business of the Lombard Odier Group, has integrated Premialab‘s industry-leading technology to support the management of their soon-to-be-launched DOM Global Macro strategy. This partnership underscores LOIM’s commitment to onboard innovative strategies in an evolving market landscape.

“Our decision to partner with Premialab is driven by their comprehensive risk management and regulatory compliance expertise,” said Didier Anthamatten, Portfolio Manager at LOIM. “With a strong track record in alternative investments, LOIM remains focused on delivering innovative investment solutions and high-quality returns for our clients. Premialab’s advanced data capabilities are essential in helping us maintain our rigorous standards and provide robust, risk-adjusted performance. Additionally, their platform perfectly matches the DOM Global Macro strategy’s needs, enhancing our risk monitoring capabilities and streamlining portfolio management.”

The DOM Global Macro strategy expects to leverage Premialab’s unique dataset. The full lookthrough across all DOM’s proprietary systematic strategies allows granular risk decomposition and scenario-based analysis at the entire portfolio level. This should help monitoring exposures’ attractiveness, from both time-series and cross-sectional perspectives, and optimizing asset allocation.

Neil Richards, Head of EMEA Business Development at Premialab, said the collaboration with LOIM is a significant addition to Premialab’s growing business in Switzerland and within the wider European markets.

“Institutions such as LOIM, which oversees a substantial portfolio across various asset classes, need continuous monitoring and adjustment to keep their investments on track,” he explained. “Premialab provides the tools for benchmarking and stress testing their systematic investments, ensuring that LOIM’s mandates are effectively managed in terms of cost, risk, and value.”

Premialab CEO Adrien Géliot highlighted that the QIS sector is experiencing rapid growth, driven by institutional investors seeking liquid, transparent, and cost-efficient investment strategies. “Premialab sits at the centre of the QIS landscape, uniquely positioned to aggregate and make sense of the vast and growing universe of data,” he stated. “We are thrilled to be partnering with LOIM to deliver our unique data and risk monitoring capabilities to one of the top global investment firms.”

Premialab’s multi-asset, multi-region platform handles 10 million data points daily. It analyzes over 5,000 investible systematic strategies, with client assets under management totalling approximately USD $20 trillion. Combining the Premialab platform with Premialab Pure Factors®, it provides comprehensive cross-asset quantitative strategy selection and thorough due diligence on strategies available worldwide. Additionally, the platform enhances risk management and reporting capabilities, including expedited and detailed regulatory reporting.

With its unique combination of systematic strategies and discretionary trading, the DOM Global Macro strategy clearly benefits from Premialab’s state-of-the art data analysis capabilities and computational efficiency. The Portfolio and Risk Managers can thus use a shared dataset for risk analysis and performance decomposition, enhancing the portfolio’s robustness and operational efficiency.

About Premialab
Premialab is the leading independent platform that collaborates with leading investment banks and institutional investors globally, providing data, analytics, and risk solutions for systematic, factor, and multi-asset strategies. With offices in London, Paris, New York, Hong Kong, Dubai and Sydney, the company has forged strong partnerships with the top 18 investment banks, asset managers, pension funds, sovereign wealth funds and insurance companies globally.

About Lombard Odier Investment Managers (LOIM)
Lombard Odier Investment Managers (LOIM) is the institutional asset management business of the Lombard Odier Group, wholly owned and funded by its partners since its establishment in 1796.

We provide a range of investment solutions to a diverse group of long-term oriented clients. Our heritage, and our combination of the best of conservatism and innovation, keeps us well positioned to create lasting value for our clients. Our investment capabilities span fixed income, convertible bonds, equities, multi-asset, and alternatives. Sustainability is central to our investment philosophy; we believe it is the founding principle of long-term economic and investment outcomes and will drive returns over the long term.

With over 200 investment professionals, we are a global business with a network of 13 offices across Europe, Asia and North America and have assets under management of CHF 64 billion (as at 31 September 2024).

View original content:https://www.prnewswire.com/de/pressemitteilungen/premialab-appointed-by-lombard-odier-investment-managers-to-scale-quantitative-investment-strategies-302306411.html

Continue Reading

Trending